Navigation Links
Medarex Announces 2007 Fourth Quarter and Year End Financial Results
Date:2/26/2008

f Clinical

Oncology (ASCO);

-- Announcing the receipt of a milestone payment from our licensing

partner, Novartis Pharma AG, in connection with the progress of ACZ885,

a fully human anti-IL-1beta antibody in Phase 3 development for the

treatment of Muckle Wells' Syndrome that was generated using Medarex's

UltiMAb(R) technology;

-- Announcing the receipt of a milestone payment from our licensing

partner, Amgen, Inc., for the advancement of an antibody into a Phase 2

clinical trial;

-- Filing the IND with the FDA for MDX-1401, a fully human second-

generation anti-CD30 antibody, in development for the treatment of

CD30-positive lymphomas;

-- Announcing the IND filing by licensing partner ImClone Systems

Incorporated for IMC-3G3, a fully human antibody that targets platelet-

derived growth factor receptor alpha for the treatment of cancer;

-- Announcing the initiation of a Phase 1 clinical trial of MEDI-545, a

fully human antibody targeting interferon-alpha, for the treatment of

psoriasis by Medarex's partner, MedImmune, Inc.;

-- Entering into separate collaboration agreements with Mitsubishi Pharma

Corporation (a subsidiary of Mitsubishi Chemical Holdings Corporation),

Organon (now part of Schering-Plough), and Compugen Ltd. to develop

fully human antibodies for the treatment of cancer and/or autoimmune

diseases;

-- Announcing the award of up to an additional $13.9 million of government

funding to Medarex's partner, PharmAthene, Inc., towards the

development of Valortim(TM) for use as an anti-toxin therapeutic to

prevent and treat inhalation anthrax infections; and

-- Adding approximately $152 million to our cash resources in 2007 through

the sale of approximately 2.6 million shares of Genmab A/S common

stock.

"We enter
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Present at the JPMorgan Small/Mid Cap Conference
5. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
6. Grupo Casa Saba Announces Fourth Quarter 2007 Results
7. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
8. Reproductive Medicine Associates of Texas Announces Open House in San Antonio
9. WallSt.net (www.WallSt.net) Announces Upcoming Interview With Chairman and CEO of flexSCAN, Inc.
10. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
11. Thomson Healthcare Announces Enhancements to Order Sets Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Getting to the bottom of Alzheimer,s disease has ... turns and controversies. In the latest crook in ... insight into the interaction between proteins associated with ... journal ACS Chemical Neuroscience , could have ... K. Surewicz, Krzysztof Nieznanski and colleagues explain that ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... few decades researchers have characterized a set of clock ... in all types of species, from flies to humans. ... researchers surmise there are more. A team from the ... wondered if big-data approaches could find them. , ... Hogenesch, PhD, professor of Pharmacology and first author Ron ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making ... . , A team of physician-scientists at UT ... (a hormone with natural anti-depressant properties) works inside the ... treatment for depression in the form of a neuroprotective ... published online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... of pregnancy among women using a newer method of ... times greater over a 10-year period than using the ... at Yale University and UC Davis has found. ... Contraception , the study found the higher risk of ... brand name Essure. , "This study provides essential ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... identified an important cancer gene that could lead to more ... a disease which currently has a poor prognosis. The ... was one of a number of significant genetic differences found ... are the most common brain tumour in children. Clinicians ...
... Up-to-Date ... , ... NJ (PRWEB) May 18, 2010 -- Projects In Knowledge ( www.projectsinknowledge.com ), a fully ... approved iPhone application developer. The company has just launched Living Medical Textbook Neurology: Multiple ...
... adds to ongoing health risks , TUESDAY, May ... of smoke, dust, fumes and gases among those involved ... Trade Center ultimately compromised the workers, sense of smell, ... diminished ability to detect odors and irritants, researchers at ...
... ... ... look like two ordinary guys, and they will even tell you that’s all they are, but ... after nearly 3 months of rollerblading across the United States. With such a grueling task, they ...
... ... the news because they are becoming more popular and may even be permanent alternatives to ... the results people want. Advancements in technology and techniques are also making these treatments ... ...
... ... played a role in the 30th Annual Texas History Day Contest; albeit, one behind the ... Irving, TX ... provider of upper extremity rehabilitation services recently played a role in the 30th Annual Texas ...
Cached Medicine News:Health News:Genetics of children's brain tumor unlocked 2Health News:Projects In Knowledge Launches Free iPhone App of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition 2Health News:Projects In Knowledge Launches Free iPhone App of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition 3Health News:Lost Sense of Smell Noted Among Ground Zero Workers Post-9/11 2Health News:Rollerbladers Finish Grueling Cross Country Trek Helped by Tahitian Noni Products 2Health News:Dr. Alexander Rivkin's Pioneering Non-Surgical Nose and Eye Transformations Are Making Headlines and May Be Permanent Solutions 2Health News:Advanced Arm Dynamics Helps Eighth Grade Students Make History 2Health News:Advanced Arm Dynamics Helps Eighth Grade Students Make History 3
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: